In a clinically relevant B16-OVA melanoma model, our spleen-targeted LNPs elicited robust antitumor immunity, characterized by retarded tumor growth, reduced tumor burden, and enhanced infiltration of cytotoxic T cells expressing granzyme B and IFN-γ. The gene discussed is GZMB; the disease is neoplasm.